TP53 mutations in epithelial ovarian cancer

被引：94

作者：

Zhang, Yu ^{[1
]}

Cao, Lan ^{[1
]}

Daniel Nguyen ^{[2
]}

Lu, Hua ^{[2
]}

机构：

[1] Cent South Univ, Xiang Ya Hosp, Dept Gynecol & Obstet, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China

[2] Tulane Univ, Sch Med, Tulane Canc Ctr, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA

来源：

TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷 / 06期

关键词：

TP53; mutation; epithelial ovarian cancer (EOC); biomarkers; prognosis; chemoresistance; therapeutic target; SYNTHETIC LETHAL INTERACTIONS; GRADE SEROUS CARCINOMA; DNA-DAMAGE RESPONSE; MUTANT P53; PLATINUM RESISTANCE; CHEMOTHERAPY; CELLS; GENE; AGGREGATION; METASTASIS;

D O I：

10.21037/tcr.2016.08.40

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Genomic sequencing analyses of a variety of human cancers have revealed that massive mutations of cancer-relevant genes are the major alterations in cancerous cells, and their mutation frequencies or rates are highly associated with the development, progression, metastasis, and drug resistance of cancers as well as their clinical outcomes and prognosis. One predominant genetic alternation in human epithelial ovarian cancer (EOC) is the mutation of TP53 that encodes the tumor suppressor p53 protein. This essay will review the most recent progress in understanding the role of TP53 mutations in development, progression, and metastasis of EOC, and discuss the potential of TP53 mutations as diagnostic and prognostic biomarkers as well as therapeutic targets for EOC.

引用

页码：650 / 663

页数：14

共 50 条

[1] TP53 Mutations in Breast and Ovarian Cancer
Silwal-Pandit, Laxmi
Langerod, Anita
Borresen-Dale, Anne-Lise
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2017, 7 (01):
[2] TP53 MUTATIONS ARE IMMUNOGENIC IN EPITHELIAL CANCER
不详
CANCER DISCOVERY, 2019, 9 (04) : 461 - 461
[3] The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
Brachova, Pavla
Thiel, Kristina W.
Leslie, Kimberly K.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2013, 14 (09) : 19257 - 19275
[4] TP53 and ovarian cancer
Schuijer, M
Berns, EMJJ
HUMAN MUTATION, 2003, 21 (03) : 285 - 291
[5] Alterations of the TP53 gene and TP53 protein expression in epithelial ovarian cancer before and after chemotherapy
Okada M.
Kigawa J.
Minagawa Y.
Kanamori Y.
Itamochi H.
Cheng X.
Ohishi T.
Terakawa N.
International Journal of Clinical Oncology, 1998, 3 (4) : 240 - 246
[6] SIGNIFICANCE OF LOCUS-SPECIFIC TP53 MUTATIONS IN OVARIAN CANCER
Knoll, K.
Berger, A.
Tsibulak, I.
Leitner, K.
Degasper, C.
Welponer, H.
Wieser, V.
Marth, C.
Fiegl, H.
Zeimet, A-G
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A139 - A139
[7] TP53 and mutations in human cancer
Szymanska, K
Hainaut, P
ACTA BIOCHIMICA POLONICA, 2003, 50 (01) : 231 - 238
[8] TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type
Rechsteiner, Markus
Zimmermann, Anne-Katrin
Wild, Peter J.
Caduff, Rosmarie
von Teichman, Adriana
Fink, Daniel
Moch, Holger
Noske, Aurelia
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2013, 95 (02) : 235 - 241
[9] TP53 mutations in head and neck cancer
Beutner, Dirk
Klussmann, Jens-Peter
Guntinas-Lichius, Orlando
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11): : 1194 - 1194
[10] TP53 mutations in head and neck cancer
Nathan, Cherie-Ann
Khandelwal, Alok R.
Wolf, Gregory T.
Rodrigo, Juan P.
Makitie, Antti A.
Saba, Nabil F.
Forastiere, Arlene A.
Bradford, Carol R.
Ferlito, Alfio
MOLECULAR CARCINOGENESIS, 2022, 61 (04) : 385 - 391

← 1 2 3 4 5 →